Phathom Pharmaceuticals Inc (PHAT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Phathom Pharmaceuticals Inc stock (PHAT) is currently trading at $10.47. Phathom Pharmaceuticals Inc PS ratio (Price-to-Sales) is 5.04. Analyst consensus price target for PHAT is $23.50. WallStSmart rates PHAT as Sell.
- PHAT PE ratio analysis and historical PE chart
- PHAT PS ratio (Price-to-Sales) history and trend
- PHAT intrinsic value — DCF, Graham Number, EPV models
- PHAT stock price prediction 2025 2026 2027 2028 2029 2030
- PHAT fair value vs current price
- PHAT insider transactions and insider buying
- Is PHAT undervalued or overvalued?
- Phathom Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- PHAT Piotroski F-Score and Altman Z-Score
- PHAT analyst price target and Smart Rating
Phathom Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Phathom Pharmaceuticals Inc (PHAT) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Phathom Pharmaceuticals Inc (PHAT) Key Strengths (2)
Revenue surging 94.10% year-over-year
83.73% of shares held by major funds and institutions
Supporting Valuation Data
Phathom Pharmaceuticals Inc (PHAT) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 25.4x book value
Premium valuation at 5.0x annual revenue
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Phathom Pharmaceuticals Inc (PHAT) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own.. Growth metrics are encouraging with Revenue Growth at 94.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (5.04), Price/Book (25.37) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -3489.00%, Operating Margin at -10.30%, Profit Margin at -126.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -3489.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 94.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PHAT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PHAT's Price-to-Sales ratio of 5.04x sits near its historical average of 5x (67th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 10% below its historical high of 5.6x set in Mar 2026, and 8% above its historical low of 4.67x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Phathom Pharmaceuticals Inc (PHAT) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Phathom Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 175M with 94% growth year-over-year. The company is currently unprofitable, posting a -126.4% profit margin.
Key Findings
Revenue growing at 94% YoY, reaching 175M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -0.01 indicates a conservative balance sheet with 135M in cash.
The company is unprofitable with a -126.4% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Phathom Pharmaceuticals Inc maintain 94%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Phathom Pharmaceuticals Inc.
Bottom Line
Phathom Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 94% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -126.4% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(21 last 3 months)
| Insider | Type | Shares |
|---|---|---|
BREEDLOVE, ROBERT CHARLES Principal Accounting Officer | Sell | -776 |
Data sourced from SEC Form 4 filings
Last updated: 8:23:54 AM
About Phathom Pharmaceuticals Inc(PHAT)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.